Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Interest & Investment Income (2020 - 2022)

Atea Pharmaceuticals has reported Interest & Investment Income over the past 3 years, most recently at $5.6 million for Q4 2022.

  • Quarterly results put Interest & Investment Income at $5.6 million for Q4 2022, up 10862.75% from a year ago — trailing twelve months through Dec 2022 was $11.2 million (up 5110.75% YoY), and the annual figure for FY2025 was $16.4 million, down 35.76%.
  • Interest & Investment Income for Q4 2022 was $5.6 million at Atea Pharmaceuticals, up from $4.4 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for AVIR hit a ceiling of $5.6 million in Q4 2022 and a floor of $7000.0 in Q3 2020.
  • Median Interest & Investment Income over the past 3 years was $55000.0 (2020), compared with a mean of $954000.0.
  • Biggest five-year swings in Interest & Investment Income: grew 1.75% in 2021 and later soared 10862.75% in 2022.
  • Atea Pharmaceuticals' Interest & Investment Income stood at $9000.0 in 2020, then skyrocketed by 466.67% to $51000.0 in 2021, then soared by 10862.75% to $5.6 million in 2022.
  • The last three reported values for Interest & Investment Income were $5.6 million (Q4 2022), $4.4 million (Q3 2022), and $1.1 million (Q2 2022) per Business Quant data.